Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel Positron Emission Tomography (PET) Radiotracers in Castration-Resistant Prostate Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 3
- 主要终点
- Functional imaging metabolic response contrasted with conventional imaging response
研究概览
简要总结
In this study 30 men, with advanced metastatic Castration-Resistant Prostate Cancer (CRPC) planned to have hormonal treatment, will undergo conventional imaging and functional imaging prior to treatment and post treatment to determine if changes in imaging results will be prognostic of outcome. Patients will have a clinical follow-up every 3 months post randomization for one year and followed for survival at Years 2 and 3.
详细描述
In this study 30 men, with advanced metastatic CRPC intended to have abiraterone acetate or enzalutamide hormonal treatment will undergo conventional imaging including a 99mTc-Methyl diphosphonate (MDP) bone scan and Computed Tomography (CT) of the abdomen and pelvis, and functional imaging with 18F-fluorodeoxyglucose (FDG) PET-CT and 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL) PET-CT one to four weeks prior to hormonal treatment and approximately 10 weeks post hormonal treatment.
Prostate Specific Antigen (PSA) will also be obtained at baseline and every three months in the first year. Baseline imaging of disease and changes between baseline and follow-up imaging on 18F-FDG PET-CT and 18F-DCFPyL PET-CT will be compared with standard of care imaging (99mTc-MDP bone scan and CT of the abdomen/pelvis) as well as with clinical evaluation including response to therapy and progression of disease.
This information could be used by clinicians to guide androgen receptor (AR) - targeted therapy. Patients will have a clinical follow-up every 3 months post randomization for one year and will be followed for survival at Years 2 and 3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Objectively documented metastatic prostate cancer progression with either of the following:
- •At least one rising PSA over a minimum of one week interval within six weeks of study registration, or
- •Radiographic progression in soft tissue and/or bone within six weeks of study registration
- •Ongoing androgen deprivation therapy with serum testosterone <50 ng/dL (<1.7 nmol/L).
- •Planned to start abiraterone acetate or enzalutamide.
排除标准
- •Age < 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status >
- •Planned to receive palliative radiotherapy within the next 12 weeks.
- •Hemoglobin < 90 g/L independent of transfusion.
- •Platelet count < 50 x 10^9 / L.
- •Serum albumin < 30 g/L.
- •Serum creatinine > 1.5 x Upper Limit of Normal (ULN) or a calculated creatinine clearance <30 L/min.
- •Contraindications to FDG.
- •Inability to lie supine for imaging with PET-CT.
- •Inability to undergo CT due to known allergy to contrast.
- •Inadequate hepatic function: (i) Bilirubin >1.5 x ULN, and (ii) Serum glutamic oxaloacetic transaminase (SGOT) >3 x ULN
- •Inability to complete the study or required follow-up
结局指标
主要结局
Functional imaging metabolic response contrasted with conventional imaging response
时间窗: 10 weeks
Percent change of the average maximum standardized uptake value (SUVmax) of target lesions in contrast with conventional imaging soft tissue and bone response between the baseline scans and the Week 10 scans.
次要结局
- Radiological progression free survival.(3 years)
- Prostate specific antigen (PSA) response(3 years)
- Progressive Disease (example change in treatment, skeletal related event)(3 years)
- Functional imaging response(10 weeks)
- Overall Survival(3 years)